What Is Ibogaine? Trump Moves To Fast-Track Psychedelic Research For PTSD Treatment

Last Updated:April 18, 2026, 22:33 IST

Ibogaine is a naturally occurring psychoactive compound extracted from the root of the Tabernanthe iboga plant.

US President Donald Trump on Saturday signed an executive order to expand research into psychedelic substances, including ibogaine, to explore their use in treating post-traumatic stress disorder (PTSD) and traumatic brain injuries (TBI), mainly among military veterans.

According to the order, the Food and Drug Administration (FDA) should update its approach to drug safety and provide clearer guidelines for researchers conducting clinical trials on substances such as psilocybin, ibogaine and other serotonin receptor agonists.

These drugs, which also include LSD and MDMA, are currently banned in the United States due to their hallucinogenic effects.

Trump highlighted the need to improve treatment options for veterans, many of whom continue to struggle with long-term mental health issues. “I’ve always believed in ensuring that the American patients have access to breakthrough treatments and therapies with love for our veterans, and I have a real love for our veterans," he said.

“Today’s order will ensure that people suffering from debilitating symptoms might finally have a chance to reclaim their lives and lead a happier life. They’ve been through so much," he added.

What Is Ibogaine?

Ibogaine, which is central to the new initiative, is a naturally occurring psychoactive compound extracted from the root of the Tabernanthe iboga plant, native to Central Africa. Traditionally used in spiritual and ceremonial practices by local communities, it has gained scientific attention for its potential in treating addiction and certain mental health conditions. However, ibogaine is currently classified as a Schedule I substance in the United States, indicating that it is considered to have no accepted medical use and a high potential for abuse.

The executive order is expected to remove some regulatory hurdles that have limited detailed research into the drug. Early findings suggest that ibogaine may help reduce cravings and withdrawal symptoms in people with substance dependence, while also offering potential benefits for PTSD.

Recent studies have explored its impact on veterans suffering from TBI and related conditions. Researchers at Stanford Medicine reported that ibogaine, when used alongside magnesium to protect heart health, showed promise in reducing symptoms of PTSD, anxiety and depression, while improving cognitive function.

In a study published in July 2025, scientists observed changes in brain activity among veterans who received the treatment. Improvements in cognitive performance were linked to increased theta brain wave activity, while a reduction in PTSD symptoms was associated with decreased complexity in certain areas of the brain.

Experts believe these changes may help the brain adapt better and reduce stress responses. However, researchers caution that evidence remains limited and further studies are needed to fully understand both the benefits and risks of ibogaine.

News world What Is Ibogaine? Trump Moves To Fast-Track Psychedelic Research For PTSD Treatment

Read More